4 recruiting, 3 not yet recruiting, 1 enrolling by invitation. 6 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Not yet recruiting 3, Recruiting 2, Enrolling by invitation 1 |
| Phase 3 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Lisaftoclax (APG-2575): new trials by email Literature Review of Lisaftoclax (APG-2575) trials Research Report on Lisaftoclax (APG-2575)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML) | Phase 2 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 73 | 2026-09-01 | 2026-09-10 |
| Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL Lisaftoclax (APG-2575), Rituximab, Pirtobrutinib - Richter Syndrome | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 23 | 2026-09-01 | 2026-09-21 |
| Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) Brentuximab Vedotin (Bv), Lisaftoclax (APG-2575) - Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Not yet recruiting | Peking University First Hospital | 46 | 2026-07-31 | 2026-07-23 |
| Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients Lisaftoclax (APG-2575) - Acute Promyelocytic Leukemia (APL) | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 20 | 2026-07-01 | 2026-06-30 |
| Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease Orelabrutinib, Rituximab (R), Lisaftoclax (APG-2575) - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Ruijin Hospital | 25 | 2025-09-10 | 2026-07-28 |
| Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). Lisaftoclax (APG-2575), Azacitidine Injection, Placebo - Higher-risk Myelodysplastic Syndrome | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 490 | 2025-01-22 | 2026-10-13 |
| A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine - CLL/SLL | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 344 | 2024-04-07 | 2026-07-28 |
| Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML Lisaftoclax (APG-2575), Reduced-dose HHT, standard-dose HHT - Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy | Phase 1 / Phase 2 | Recruiting | Ascentage Pharma Group Inc. | 682 | 2020-09-28 | 2026-04-29 |
Leukemia, Myeloid, Acute (2) · Leukemia, Promyelocytic, Acute (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Primary Cutaneous Anaplastic Large Cell (1) · Mycosis Fungoides (1) · Neoplasm, Residual (1)
Ascentage Pharma Group Inc. (3) · Guangdong Second Provincial General Hospital (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Peking University First Hospital (1) · Ruijin Hospital (1) · The Affiliated People's Hospital of Ningbo University (1)
China (7) · Australia (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Norway (1) · Poland (1) · Spain (1)
Guillermo Garcia-Manero, M.D. (1) · Guopan Yu, PhD (1) · Jie Jin, M.D. (1) · Keshu Zhou, M.D., Ph.D. (1) · Lugui Qiu, M.D., Ph.D. (1) · Xiaojun Huang, M.D., Ph.D. (1) · Yifan Zhai, M.D., Ph.D. (1)